Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

503 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model.
Nakahara H, Ono A, Hayes CN, Shirane Y, Miura R, Fujii Y, Murakami S, Yamaoka K, Bao H, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Oka S; Hiroshima Liver Study Group; TransSCOT Consortium. Nakahara H, et al. Among authors: miura r. JCO Clin Cancer Inform. 2024 Dec;8:e2400108. doi: 10.1200/CCI.24.00108. Epub 2024 Dec 18. JCO Clin Cancer Inform. 2024. PMID: 39693579
Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Miura R, Ono A, Nakahara H, Shirane Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Kishi T, Ohishi W, Sakamoto N, Arihiro K, Hayes CN, Oka S. Miura R, et al. J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02185-w. Online ahead of print. J Gastroenterol. 2024. PMID: 39652104
Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial).
Sato Y, Shimizu S, Ueda K, Suzuki T, Suzuki S, Miura R, Ando M, Tsuda K, Iwata O, Muramatsu Y, Kidokoro H, Hirakawa A, Hayakawa M; SHEILD team. Sato Y, et al. Among authors: miura r. Stem Cells Transl Med. 2024 Nov 12;13(11):1053-1066. doi: 10.1093/stcltm/szae071. Stem Cells Transl Med. 2024. PMID: 39401019 Free PMC article.
Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.
Miura R, Ono A, Yano S, Amioka K, Naruto K, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Nakahara T, Murakami E, Kawaoka T, Miki D, Tsuge M, Hayes CN, Oka S. Miura R, et al. Medicine (Baltimore). 2024 Aug 23;103(34):e39289. doi: 10.1097/MD.0000000000039289. Medicine (Baltimore). 2024. PMID: 39288227 Free PMC article.
Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma.
Uchikawa S, Kawaoka T, Murakami S, Miura R, Shirane Y, Johira Y, Kosaka M, Fujii Y, Fujino H, Ono A, Murakami E, Miki D, Hayes CN, Tsuge M, Oka S. Uchikawa S, et al. Among authors: miura r. Hepatol Res. 2024 Aug 17. doi: 10.1111/hepr.14104. Online ahead of print. Hepatol Res. 2024. PMID: 39152708
503 results